On October 11, 2024, Bernd Seizinger, Director at Aprea Therapeutics Inc (APRE, Financial), purchased 10,000 shares of the company. The transaction was documented in a recent SEC Filing. Following this acquisition, the insider now owns 44,730 shares of Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Insider buying is often regarded as a positive signal about a company's future prospects, as insiders may buy shares based on their expectations of future performance.
Over the past year, Bernd Seizinger has increased his holdings in the company by purchasing a total of 16,860 shares, with no recorded sales. This recent purchase was made when shares were priced at $2.68, valuing the transaction at approximately $26,800. The company's market cap following this transaction stands at $14.286 million.
The insider transaction history for Aprea Therapeutics Inc shows a trend of more insider buying than selling. Over the last year, there have been seven insider buys and no insider sells.
For investors considering the stock's valuation metrics, the current share price and GF Value are critical. Additionally, investors may look at other financial ratios such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow to gauge the stock's potential.
This insider buying activity could be a signal to shareholders and potential investors about the confidence insiders have in the company's direction and potential for growth.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
